8-K: Nektar Therapeutics Reports First Quarter 2025 Financial Results

Nektar Therapeutics announced its first quarter 2025 financial results, highlighting progress in clinical trials and a decrease in year-over-year revenue due to the sale of its manufacturing facility.

Summary

• Nektar Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• Cash and investments totaled $220.7 million as of March 31, 2025, compared to $269.1 million at the end of 2024.
• The company expects its cash and marketable securities to fund operations into the fourth quarter of 2026.
• Revenue for the first quarter of 2025 was $10.5 million, down from $21.6 million in the same period of 2024, due to the sale of the Huntsville manufacturing facility.
• Total operating costs and expenses decreased to $55.0 million from $57.1 million year-over-year.
• R&D expenses increased to $30.5 million from $27.4 million, driven by rezpegaldesleukin development.
• G&A expenses rose to $24.3 million from $20.1 million, primarily due to increased legal expenses.
• The company reported a net loss of $50.9 million, or $0.24 per share, compared to a net loss of $36.8 million, or $0.19 per share, in the first quarter of 2024.
• Excluding a $4.5 million non-cash loss from an equity method investment, the non-GAAP net loss was $46.4 million, or $0.22 per share.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials and has a decent cash runway, the increased net loss and decreased revenue are concerning.

Positives

• Cash runway extends into the fourth quarter of 2026.
• Phase 2 data for rezpegaldesleukin in atopic dermatitis and alopecia areata are expected in June and December 2025, respectively.
• IND submission for NKTR-0165 is targeted for the end of 2025.
• The FDA granted Fast Track designation for rezpegaldesleukin for atopic dermatitis.
• Target enrollment was completed in the Phase 2b clinical trial of rezpegaldesleukin in severe-to-very severe alopecia areata.
• A new clinical trial agreement was established with TrialNet to evaluate rezpegaldesleukin in a Phase 2 study of patients with new onset type 1 diabetes mellitus.
• Nektar collaborators at the Fred Hutchinson Cancer Center had an abstract selected for oral presentation at the 30th annual EHA Congress.

Negatives

• Revenue decreased year-over-year due to the sale of the Huntsville manufacturing facility.
• Net loss increased to $50.9 million from $36.8 million year-over-year.
• Cash and investments decreased from $269.1 million at the end of 2024 to $220.7 million as of March 31, 2025.
• The company experienced a $4.5 million non-cash loss from its equity method investment in Gannet BioChem.

Risks

• The therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue.
• Rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies.
• The timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets.
• A Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States.
• Patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required.

Future Outlook

Nektar expects its cash and marketable securities to support strategic development activities and operations into the fourth quarter of 2026. The company anticipates reporting topline data from Phase 2 studies of rezpegaldesleukin in atopic dermatitis and alopecia areata in June and December 2025, respectively. Nektar is also targeting the submission of the IND for NKTR-0165 at the end of 2025.

Management Comments

• We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis, said Howard W. Robin, President and CEO of Nektar.
• These data will be followed by the topline data from the Phase 2 study of rezpegaldesleukin in patients with alopecia areata in December of this year.
• The results of both randomized studies will demonstrate the potential of rezpegaldesleukin to provide a new treatment paradigm for patients with these serious dermatological diseases.
• As a first-in-class T regulatory cell biologic, rezpegaldesleukin is poised to emerge as an important novel mechanism to treat millions of patients with chronic autoimmune disorders.
• We are also on track to complete our IND-enabling work for NKTR-0165, our unique antibody targeting the TNFR2 receptor, that has the potential to be developed as a treatment for multiple sclerosis, ulcerative colitis and vitiligo, continued Robin.
• We are targeting the submission of the IND for NKTR-0165 at the end of this year.
• Additionally, we are making significant progress on our new bispecific antibody, NKTR-0166.
• This antibody incorporates a TNFR2 epitope with a validated antibody target and is advancing into preclinical studies.

Industry Context

Nektar's focus on autoimmune and chronic inflammatory diseases aligns with a growing area of pharmaceutical research and development. The development of novel biologics like rezpegaldesleukin, targeting T regulatory cells, represents a potentially significant advancement in treating these conditions. The company's pipeline, including NKTR-0165 and NKTR-0166, reflects a broader industry trend towards bispecific antibodies and targeted therapies.

Comparison to Industry Standards

• Nektar's cash runway into Q4 2026 is a critical metric, especially when compared to other clinical-stage biotech companies.
• Companies like Madrigal Pharmaceuticals, which is developing therapies for liver diseases, and Viking Therapeutics, focused on metabolic disorders, are often benchmarked against Nektar in terms of cash burn and clinical trial progress.
• The FDA's Fast Track designation for rezpegaldesleukin is a positive signal, but its ultimate impact depends on clinical trial outcomes and regulatory review, similar to how Fast Track designations have played out for companies like Biohaven in neurology.
• The decrease in revenue due to the sale of the Huntsville facility is a strategic shift, and its success will be judged by how effectively Nektar can focus on its core R&D activities, a common challenge for companies restructuring their operations.

Stakeholder Impact

• Shareholders will be concerned about the increased net loss and decreased revenue.
• Employees may be affected by the restructuring and sale of the manufacturing facility.
• Patients with autoimmune and chronic inflammatory diseases may benefit from the development of new treatments.
• The company's financial performance may impact its relationships with suppliers and creditors.

Next Steps

• Report topline data from the Phase 2 study of rezpegaldesleukin in atopic dermatitis in June 2025.
• Report topline data from the Phase 2 study of rezpegaldesleukin in alopecia areata in December 2025.
• Submit the IND for NKTR-0165 at the end of 2025.
• Advance NKTR-0166 into preclinical studies.

Key Dates

Keywords

Nektar Therapeutics, rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, NKTR-255, Financial Results, Clinical Trials, Atopic Dermatitis, Alopecia Areata, Autoimmune Disorders, R&D, FDA Fast Track